News - Anti-Arthritics/Rheumatics

Filter

Popular Filters

20 to 44 of 297 results

EMA pharmacovigilance unit calls for suspension of Protelos/Osseor

EMA pharmacovigilance unit calls for suspension of Protelos/Osseor

10-01-2014

The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) has recommended…

Anti-Arthritics/RheumaticsEuropeOsseorPharmaceuticalProtelosRegulationServierWomen's Health

Ranbaxy and EPIRUS sign licensing agreement for Infliximab biosimilar

Ranbaxy and EPIRUS sign licensing agreement for Infliximab biosimilar

09-01-2014

India's largest drugmaker Ranbaxy Laboratories (BSE: 500359) and EPIRUS Switzerland, a wholly-owned subsidiary…

Anti-Arthritics/RheumaticsBiosimilarsEPIRUS BiopharmaceuticalsGastro-intestinalsIndiainfliximabLicensingRanbaxy LaboratoriesRemicade

Amgen and UCB’s romosozumab shows significant increase in BMD

Amgen and UCB’s romosozumab shows significant increase in BMD

02-01-2014

US biotech firm Amgen and partner UCB of Belgium have announced positive results from a Phase II trial…

AmgenAnti-Arthritics/RheumaticsBiotechnologyForteoFosamaxResearchromosozumabUCB

UK’s NICE draft guidance negative on Stelara for psoriatic arthritis

UK’s NICE draft guidance negative on Stelara for psoriatic arthritis

27-12-2013

UK drugs watchdog the National Institute for Health and Care Excellence (NICE) has opened a consultation…

Anti-Arthritics/RheumaticsEuropeJanssenJohnson & JohnsonPharmaceuticalPricingRegulationStelara InjectionUK

Biologics reimbursement trends in Argentina, Brazil and Mexico

Biologics reimbursement trends in Argentina, Brazil and Mexico

23-12-2013

Novel biologics must demonstrate improvements in efficacy, safety and cost-benefit compared with currently…

Anti-Arthritics/RheumaticsArgentinaBiotechnologyBrazilMalaysiaMarkets & MarketingOncologyPricingSouth America

Rapid uptake of rheumatoid arthritis biosimilars expected in Brazil and Mexico

19-12-2013

Biosimilars will be quickly acquired and used in public health institutions in the treatment of patients…

Anti-Arthritics/RheumaticsBiosimilarsBrazilGenericsMarkets & MarketingRegulationSouth America

Ipsen prepares for EU resupply of Increlex; enters deal with Mayoly Spindler

Ipsen prepares for EU resupply of Increlex; enters deal with Mayoly Spindler

18-12-2013

French drugmaker Ipsen says that Lonza has successfully re-manufactured the active ingredient of Increlex…

Anti-Arthritics/RheumaticsEuropeGastro-intestinalsIncrelexIpsenLonzaMarkets & MarketingMayoly SpindlerPharmaceuticalProductionRare diseases

Biogen Idec and Samsung Bioepis to market anti-TNF biosimilars in Europe

Biogen Idec and Samsung Bioepis to market anti-TNF biosimilars in Europe

17-12-2013

US biotech major Biogen Idec has exercised its right to enter into an agreement to commercialize anti-TNF…

Anti-Arthritics/RheumaticsBiogen IdecBiosimilarsBiotechnologyEuropeMarkets & MarketingSamsung Bioepis

AstraZeneca lesinurad meets Ph III goal in gout patients

AstraZeneca lesinurad meets Ph III goal in gout patients

16-12-2013

Anglo-Swedish drug major AstraZeneca has released positive top-line results from LIGHT, a Phase III…

Anti-Arthritics/RheumaticsAstraZenecaInflammatory diseaseslesinuradPharmaceuticalResearch

Savient to sell out to Crealta Pharma for around $120 million

12-12-2013

US drugmaker Savient Pharmaceuticals, which recently elected to file voluntary bankruptcy protection…

Anti-Arthritics/RheumaticsCrealta PharmaceuticalsKrystexxaMergers & AcquisitionsPharmaceuticalSavient Pharmaceuticals

DMC clears Merck & Co’s Alzheimer’s drug MK-8931 development

DMC clears Merck & Co’s Alzheimer’s drug MK-8931 development

10-12-2013

The development program for MK-8931, a novel investigational oral beta-amyloid precursor protein site-cleaving…

Anti-Arthritics/RheumaticsFinancialFosamaxMerck & CoMK-8931NeurologicalNorth AmericaPharmaceuticalResearch

Report: Approval of first biosimilar MAb in Europe has major implications for 2014 and beyond

Report: Approval of first biosimilar MAb in Europe has major implications for 2014 and beyond

07-12-2013

Key clinical, corporate and regulatory events affecting the biosimilar industry have been identified…

Anti-Arthritics/RheumaticsBiosimilarsCellTrionEuropeGenericsHospiraInflammatory diseasesInflectraMarkets & MarketingRegulationRemsima

Health Canada clears AbbVie’s Humira for UC

Health Canada clears AbbVie’s Humira for UC

28-11-2013

In what is now the eighth indication in Canada for its top-selling drug Humira (adalimumab), US drugmaker…

AbbVieAnti-Arthritics/RheumaticsGastro-intestinalsHumiraNorth AmericaPharmaceuticalRegulation

CleveXel Pharma and Dynamix to develop oral treatment for RA

25-11-2013

CleveXel Pharma has entered into a partnering agreement with venture-backed Israeli biopharmaceutical…

Anti-Arthritics/RheumaticsCleveXel PharmaDynamix PharmaceuticalsEuropeLicensingPharmaceuticalResearchRest of the World

Sanofi and Regeneron report positive Phase III results with sarilumab in RA

Sanofi and Regeneron report positive Phase III results with sarilumab in RA

22-11-2013

French drug major Sanofi (Euronext: SAN) and US partner Regeneron Pharmaceuticals (Nasdaq: REGN) have…

Anti-Arthritics/RheumaticsEuropeNorth AmericaPharmaceuticalRegeneronResearchSanofisarilumabUSA

Merck Serono collaborates with Biopharm GmbH on osteoarthritis research

Merck Serono collaborates with Biopharm GmbH on osteoarthritis research

20-11-2013

Privately-held Biopharma GmbH says it has signed an agreement with Merck Serono, the biopharma subsidiary…

Anti-Arthritics/RheumaticsBiopharm GmbHMerck KGaAMerck SeronoPharmaceuticalResearch

Horizon Pharma gets US rights for Vimovo from AstraZeneca

Horizon Pharma gets US rights for Vimovo from AstraZeneca

19-11-2013

USA-based Horizon Pharma has entered into an agreement to acquire from Anglo-Swedish drug major AstraZeneca…

Anti-Arthritics/RheumaticsAstraZenecaHorizon PharmaLicensingNorth AmericaPharmaceuticalPozenVimovo

Horizon Pharma and Mundipharma in deal for Lodotra in Middle East and Africa

11-11-2013

USA-based Horizon Pharma has signed an exclusive agreement with privately-held Swiss drugmaker Mundipharma…

Anti-Arthritics/RheumaticsHorizon PharmaLicensingLodotraMundipharmaPharmaceuticalRest of the World

EMA Pharmacovigilance unit updates on Iclusig, diacerein and acipimox

EMA Pharmacovigilance unit updates on Iclusig, diacerein and acipimox

09-11-2013

At its November 4-7 meetings, the European Medicines Agency’s Pharmacovigilance Risk Assessment Committee…

acipimoxAnti-Arthritics/RheumaticsAriad PharmaceuticalsCardio-vasculardiacereinEuropeIclusigOncologyPharmaceuticalRegulation

Brazil’s MoH partners with Merck Serono to invest $430 million in bio-pharma production

Brazil’s MoH partners with Merck Serono to invest $430 million in bio-pharma production

08-11-2013

The Brazilian Ministry of Health is managing a series of product development partnerships and the selection…

Anti-Arthritics/RheumaticsBionovisBiotechnologyFinancialMerck KGaAMerck SeronoOncologyProductionSouth America

Positive new data on Bristol-Myers’s clazakizumab and nivolumab

Positive new data on Bristol-Myers’s clazakizumab and nivolumab

29-10-2013

US drug major Bristol-Myers Squibb and partner privately-held Alder Biopharmaceuticals have presented…

Alder BiopharmaceuticalsAnti-Arthritics/RheumaticsBristol-Myers SquibbclazakizumabnivolumabOncologyPharmaceuticalResearch

Roche and Chugai’s SC RoActemra improves RA long term

Roche and Chugai’s SC RoActemra improves RA long term

28-10-2013

Roche and its majority-owned Japanese subsidiary Chugai Pharmaceutical have announced that their RoActemra…

Anti-Arthritics/RheumaticsAsia-PacificChugai PharmaceuticalPharmaceuticalResearchRoActemraRoche

European prescribing attitudes for rheumatoid arthritis post-ADACTA

European prescribing attitudes for rheumatoid arthritis post-ADACTA

28-10-2013

Results from the ADACTA trial, which showed that Swiss drug major Roche’s RoActemra (tocilizumab) is…

AbbVieAnti-Arthritics/RheumaticsBiotechnologyEuropeHumiraMarkets & MarketingPfizerRoActemraRochetofactinib

Genentech’s SC Actemra approved by US FDA for severe RA

Genentech’s SC Actemra approved by US FDA for severe RA

22-10-2013

Genentech has announced that the US Food and Drug Administration has approved a subcutaneous formulation…

ActemraAnti-Arthritics/RheumaticsGenentechNorth AmericaPharmaceuticalRegulationRoche

20 to 44 of 297 results

Back to top